Osiris Therapeutics, Inc. Announces Peer-Reviewed Publication Demonstrating That Lyopreservation Method Developed for Living ...
02 Outubro 2018 - 5:30PM
Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine
company focused on developing and marketing products for wound
care, orthopedics, and sports medicine, announced today that a new
peer-reviewed manuscript entitled “Properties of Viable
Lyopreserved Amnion Are Equivalent to Viable Cryopreserved Amnion
with the Convenience of Ambient Storage” has been published in PLOS
ONE and is available online
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0204060.
In the published study the structural, molecular, and wound
relevant properties of a lyopreserved human amniotic membrane were
compared with the properties of a cryopreserved human amniotic
membrane. Results showed that the structure, growth factors, and
cell viability of the lyopreserved amnion are comparable to that of
cryopreserved and fresh amnions. Properties of lyopreserved and
cryopreserved amniotic membranes were tested in vivo in a diabetic
mouse chronic wound model, which mimics impaired wound healing
reported in diabetic patients. Both lyopreserved and cryopreserved
amnion weekly applications resulted in wound closure by day 35
whereas in the saline gel control group of animals wounds became
larger.
“We are very pleased to announce this scientific publication
describing properties of amniotic tissue processed by the
lyopreservation method developed by the Osiris R&D team,” said
Dr. Alla Danilkovitch, Chief Scientific Officer. “The data supports
that the new tissue preservation method is similar to
cryopreservation in that it retains all native components of fresh
amnion, however it eliminates ‘cold chain’ constraints.”
About Osiris Therapeutics
Osiris Therapeutics, Inc., based in Columbia,
Maryland, researches, develops, manufactures and commercializes
regenerative medicine products intended to improve the health and
lives of patients and lower overall healthcare costs. We have
achieved commercial success with products in orthopedics, sports
medicine and wound care, including the Grafix product line,
Stravix®, BIO4® and Cartiform®. We continue to advance our
research and development by focusing on innovation in regenerative
medicine, including the development of bioengineered stem cell and
tissue‑based products. Osiris®, Grafix®, GrafixPL®, GrafixPL
PRIME™ Cartiform®, and Prestige Lyotechnologysm are our trademarks.
BIO4® is a trademark of Howmedica Osteonics Corp., a subsidiary of
Stryker Corporation. More information can be found on the Company’s
website, www.Osiris.com. (OSIR-G)
Forward-Looking Statements
Statements herein relating to the future of
Osiris Therapeutics, Inc. and the ongoing research and development
of our products are forward-looking statements. Osiris
Therapeutics, Inc. cautions that these forward-looking statements
are subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those expressed or implied
by such statements. These risks and uncertainties include
those identified under the heading “Risk Factors” in the Osiris
Therapeutics Inc. Annual Report on Form 10-K for the years ended
December 31, 2017, 2016 and 2015 and Quarterly Report on Form 10-Q
for the quarters ended March 31, 2018 and June 30, 2018, as filed
with the Securities and Exchange Commission (SEC). We caution
investors not to place considerable reliance on the forward-looking
statements contained in this press release. Examples of
forward-looking statements may include, without limitation,
statements regarding the anticipated efficiencies and advantages of
products and the likelihood of customer clinical adoption of any
new products. Although well characterized in scientific
literature and studies, preservation of tissue integrity, including
cells, may not be indicative of clinical outcome.
Accordingly, you should not unduly rely on these forward-looking
statements. You are encouraged to read our filings with the SEC,
available at sec.gov, for a discussion of these and other risks and
uncertainties. The forward-looking statements in this press
release speak only as of the date of this document, and we
undertake no obligation to update or revise any of the
statements. Our business is subject to substantial risks and
uncertainties, including those referenced above. Investors,
potential investors, and others should give careful consideration
to these risks and uncertainties.
For additional information, please
contact:Diane SavoieOsiris Therapeutics, Inc.(443)
545-1834OsirisPR@Osiris.com
Osiris Therapeutics, Inc. (NASDAQ:OSIR)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Osiris Therapeutics, Inc. (NASDAQ:OSIR)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024